Metformin represses cancer cells via alternate pathways in N-cadherin expressing vs. N-cadherin deficient cells

Oncotarget

Volumn 6, Issue 30, 2015, Pages 28973-28987

  Ge, Rongbin ^a   Wang, Zongwei ^a   Wu, Shulin ^a   Zhuo, Yangjia ^a,b   Otsetov, Aleksandar G ^a   Cai, Chao ^a,b   Zhong, Weide ^a,b   Wu, Chin Lee ^a   Olumi, Aria F ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Metformin; N cadherin; Prostate cancer; TWIST

Indexed keywords

ADENYLATE KINASE; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METFORMIN; NERVE CELL ADHESION MOLECULE; PROTEIN TWIST1; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CADHERIN; CDH2 PROTEIN, HUMAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LEUKOCYTE ANTIGEN; NUCLEAR PROTEIN; PRKAA1 PROTEIN, HUMAN; RELA PROTEIN, HUMAN; TRANSCRIPTION FACTOR RELA; TWIST RELATED PROTEIN 1; TWIST1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RECURRENCE; CANCER RESISTANCE; COHORT ANALYSIS; CONCENTRATION RESPONSE; ENZYME ACTIVATION; GLEASON SCORE; HUMAN; HUMAN CELL; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MITOSIS INHIBITION; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; WILD TYPE; ADJUVANT CHEMOTHERAPY; ANIMAL; CELL PROLIFERATION; COMPARATIVE STUDY; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; MCF-7 CELL LINE; METABOLISM; NUDE MOUSE; PATHOLOGY; PROSTATIC NEOPLASMS; RNA INTERFERENCE; SURVIVAL ANALYSIS; TIME FACTOR; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR RECURRENCE;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; APOPTOSIS; CADHERINS; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MCF-7 CELLS; METFORMIN; MICE, NUDE; NEOPLASM RECURRENCE, LOCAL; NUCLEAR PROTEINS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TIME FACTORS; TRANSCRIPTION FACTOR RELA; TRANSFECTION; TREATMENT OUTCOME; TWIST-RELATED PROTEIN 1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84945156936     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5023     Document Type: Article

References (34)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011 the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 61:212-236.
2. CDC: National Diabetes Statistics Report. 2014;
3. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. Bmj. 2005; 330:1304-1305.
4. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009; 27:3297-3302.
5. Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, Austin PC, Fleshner N. Metformin Use and All-Cause and Prostate Cancer-Specific Mortality Among Men With Diabetes. J Clin Oncol. 31:3069-3075.
6. Preston MA, Riis AH, Ehrenstein V, Breau RH, Batista JL, Olumi AF, Mucci LA, Adami HO, Sorensen HT. Metformin Use and Prostate Cancer Risk. Eur Urol.
7. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006; 66:10269-10273.
8. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther. 9:1092-1099.
9. Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le Marchand-Brustel Y, Auberger P, Tanti JF, Giorgetti-Peraldi S, Bost F. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 71:4366-4372.
10. Kato K, Gong J, Iwama H, Kitanaka A, Tani J, Miyoshi H, Nomura K, Mimura S, Kobayashi M, Aritomo Y, Kobara H, Mori H, Himoto T, Okano K, Suzuki Y, Murao K, et al. The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther. 11:549-560.
11. Zhuang Y, Miskimins WK. Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal. 2008; 3:18.
12. Zhang X, Zhang L, Yang H, Huang X, Otu H, Libermann TA, DeWolf WC, Khosravi-Far R, Olumi AF. c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells. Cancer Res. 2007; 67:9425-9434.
13. Ge R, Wang Z, Zeng Q, Xu X, Olumi AF. F-box protein 10, an NF-kappaB-dependent anti-apoptotic protein, regulates TRAIL-induced apoptosis through modulating c-Fos/c-FLIP pathway. Cell Death Differ. 18:1184-1195.
14. Dan HC, Cooper MJ, Cogswell PC, Duncan JA, Ting JP, Baldwin AS. Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. Genes Dev. 2008; 22:1490-1500.
15. Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature. 1999; 401:86-90.
16. Tatsuya Shimomura EK, Tran Chao P., Yamashiro Joyce, Wainberg Zev A., Reiter Robert E. N-cadherin monoclonal antibody as a therapeutic agent against chemoresistance in prostate cancer. Cancer Research. 2011; 71. Abstract nr 5052.
17. Hui L, Zhang S, Dong X, Tian D, Cui Z, Qiu X. Prognostic significance of twist and N-cadherin expression in NSCLC. PLoS One. 8:e62171.
18. Alexander NR, Tran NL, Rekapally H, Summers CE, Glackin C, Heimark RL. N-cadherin gene expression in prostate carcinoma is modulated by integrin-dependent nuclear translocation of Twist1. Cancer Res. 2006; 66:3365-3369.
19. Chung S, Yao J, Suyama K, Bajaj S, Qian X, Loudig OD, Eugenin EA, Phillips GR, Hazan RB. N-cadherin regulates mammary tumor cell migration through Akt3 suppression. Oncogene. 32:422-430.
20. Vesuna F, Lisok A, Kimble B, Domek J, Kato Y, van der Groep P, Artemov D, Kowalski J, Carraway H, van Diest P, Raman V. Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-alpha. Oncogene. 31:3223-3234.
21. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care. 2002; 25:2244-2248.
22. Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med. 9:33.
23. Penney KL, Stampfer MJ. The time is ripe for a randomized trial of metformin in clinically localized prostate cancer. J Clin Oncol. 31:3054-3055.
24. Blandino G, Valerio M, Cioce M, Mori F, Casadei L, Pulito C, Sacconi A, Biagioni F, Cortese G, Galanti S, Manetti C, Citro G, Muti P, Strano S. Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC. Nat Commun. 3:865.
25. Hirsch HA, Iliopoulos D, Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci U S A. 110:972-977.
26. Shintani Y, Fukumoto Y, Chaika N, Grandgenett PM, Hollingsworth MA, Wheelock MJ, Johnson KR. ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression. Int J Cancer. 2008; 122:71-77.
27. Augustine CK, Yoshimoto Y, Gupta M, Zipfel PA, Selim MA, Febbo P, Pendergast AM, Peters WP, Tyler DS. Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment. Cancer Res. 2008; 68:3777-3784.
28. Zhang X, Jin TG, Yang H, DeWolf WC, Khosravi-Far R, Olumi AF. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factorrelated apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res. 2004; 64:7086-7091.
29. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol. 2009; 1:a001651.
30. Hao L, Ha JR, Kuzel P, Garcia E, Persad S. Cadherin switch from E-to N-cadherin in melanoma progression is regulated by the PI3K/PTEN pathway through Twist and Snail. Br J Dermatol. 166:1184-1197.
31. Oda H, Tsukita S, Takeichi M. Dynamic behavior of the cadherin-based cell-cell adhesion system during Drosophila gastrulation. Dev Biol. 1998; 203:435-450.
32. Khan MA, Chen HC, Zhang D, Fu J. Twist: a molecular target in cancer therapeutics. Tumour Biol. 34:2497-2506.
33. Hsien-Ming Wu AVS, Leung Peter C.K. Growth hormonereleasing hormone (GHRH) antagonist attenuates cell motility of human endometrial cancer by down-regulating Twist and N-Cadherin expression. Cancer Research. 2013; 73.
34. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999; 59:5002-5011.